Research & Development

Strativa's Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA

June 16, 2009

Loramyc is currently marketed in several EU territories
 
 
 

Eli Lilly and Company Announces New Drug Discovery Initiative

June 15, 2009

Goal is to foster open collaboration between Lilly and global laboratory researchers
 

New Study Shows Javelin Pharmaceutical's DylojectTM Well-Tolerated in High-Risk Patients with Impaired Renal and Hepatic Function

June 15, 2009

The Company plans to file a New Drug application during the fall of 2009
 

FDA Accepts Final Section of NDA Filing for LUCASSIN(R)

June 12, 2009

Priority Review Granted
 

DxNA Submits its Rapid Detection Platform Test for H1N1 to FDA

June 09, 2009

Company's Portable 4.5kg "Lab in a Box" Allows for Rapid Onsite Pathogen Detection
 
 

Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring

June 04, 2009

Company to Focus Operations on Continuing the Advancement of ANA598
 

Positive Outcome Reached at 16 Weeks for Avexa's ATC Phase III Trial

June 04, 2009

DSMB recommends continuation of the ATC Phase III Trial after review of the data
 

PPD Announces Takeda to Conduct Additional Study for Alogliptin MAA in the EU

June 03, 2009

Takeda to postpone MAA submissions for alogliptin and alogliptin/ACTOS
 

NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia

June 02, 2009

Potential Seven Years Market Exclusivity in PHN Pending Product Approval
 

Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment

May 11, 2009

Oforta is currently approved in the U.S. for use as a second-line therapy to treat adults with B-cell CLL
 

ACADIA Pharmaceuticals and Biovail Form Collaboration to Develop and Commercialize Pimavanserin in North America

May 04, 2009

Pimavanserin is a new chemical entity (NCE) currently in Phase III development
 

Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion

April 30, 2009

Two Phase 3 studies to start in the second half of this year
 

Simulations Plus Releases DDDPlus Version 3.0

April 29, 2009

Major Update to One-of-a-Kind Software Increases Value to Formulation Scientists
 

Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma

April 29, 2009

Final DMB Safety Review and Futility Analysis Next Month
 

Skinvisible's DermSafe(R) Hand Sanitizer Kills Swine Flu Virus

April 28, 2009

Prevention Available to Combat Spread of Viruses
 

Isotechnika announces Phase 3 ESSENCE data meets primary endpoint in psoriasis

April 28, 2009

ESSENCE study results confirm the safety profile of voclosporin
 

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

April 27, 2009

Trial Will Build on Pivotal Phase III Study for the Treatment of Advanced Prostate Cancer
 

Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint

April 22, 2009

Genentech and Roche Remain Committed to Avastin Adjuvant Colon, Breast and Lung Cancer Programs
 

Alkermes Completes Enrollment for Registration Study of VIVITROL in Patients with Opioid Dependence

April 21, 2009

Clinical Development Program Expanded with Phase 3b Study in Healthcare Professionals
 

Cerulean Pharma Inc. Announces Appointment of Oliver S. Fetzer as President and CEO

April 08, 2009

Alan L. Crane named Chairman of the Board
 

Latest News

Popular Topics
Acquisition Agency Animal Health Biopharmaceutical Biotech Business Clinical Management Collaboration Diagnostic Marketing & Communications Medical Device Medical Equipment Merger New Hire New Hires Personnel Pharmaceutical Pharmaceutical Products Pipeline Product Acquisition Product Launch Product Promotion Regulatory Regulatory Approval Research & Development